Juvion Health Sciences SA

Improving health span in the elderly: Nurturing motion

Juvion’s vision is to redefine aging biology. We aim to prove that age-related loss of movement and memory is driven by weakening cell communication in the nervous system, and that it can be restored with the right compounds. Our focus is strengthening neuron-to-muscle signaling for mobility and neuron-to-neuron signaling for memory and cognition. We are building a high-throughput in vivo discovery system powered by machine vision and real aging biology data, enabling rapid testing of hundreads of compounds and deep real time tracking across life stages. Our core models and assays remain fully protected, ensuring a unique and defensible class of Juvion compounds. Juvion001 is our first step toward therapies that restore strength, mobility, and preserve memory.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
Milestone

02.05.2025

Manufacturing JUV-001 for Pilot market entry

Milestone

15.04.2025

Preclinical validation and toxicology analysis

Deal

04.12.2024

Transformation of the Juvion platform into a fully automated system – Transition from academia to industry level.

Milestone

14.11.2024

Identification of first lead compound-JUV-001

Milestone

25.10.2024

Innosuisse initial coaching

No Jobs

No videos and documents

EPFL Spin-Off

Website

Venture Leaders Biotech

Juvion Health Sciences SA

Improving health span in the elderly: Nurturing motion

Headquarter:
Lausanne

Foundation Date:
July 2024

Technology:

  • Biotech

Sectors:

  • Biotech
  • Digital Health
  • Drug discovery
  • Machine Learning / AI
  • Robotics
  • Research and development
  • Neurology

Support received

  • Support venture leaders